The Bluffs Addiction Campuses Unveils Special Forces Veteran Kyle Morgan's Journey of Recovery
SHERRODSVILLE, Ohio, March 10, 2025 (GLOBE NEWSWIRE) -- The Bluffs Addiction Campuses unveiled the inspiring recovery journey of Kyle Morgan, a retired Special Forces Green Beret and CEO of Blu Bearing Solutions. During a special event on February 28, Morgan shared his personal experience of overcoming trauma and addiction with patients and staff. With two decades of military service, including deployments to Iraq and Afghanistan, Morgan reflected on his struggles with substance use and the turning point that led him to long-term sobriety.
Dr. Brian Wind and Kyle Morgan at The Bluffs Addiction Campuses, discussing addiction treatment, trauma recovery, Y6R and resilience.
Morgan was awarded the Distinguished Service Cross—the second-highest U.S. military award for valor—for his extraordinary heroism during the 2015 terrorist attack at the Radisson Blu Hotel in Bamako, Mali. Among his numerous decorations are five Bronze Star Medals (one with valor) and three Presidential Unit Citations, a testament to his unwavering commitment to his fellow service members and the American values he swore to defend.
Now CEO of Blu Bearing Solutions, Morgan delivered a powerful address on recovery and resilience, sharing his deeply personal journey through addiction, trauma, and eventual recovery.
'Hopelessness is the most scared space I've ever been in my life,' Morgan told attendees. 'Not any operational environment has been as frightening as that space of complete despair.'
He recounted how the Mali hotel attack became a pivotal turning point in his life. Despite facing countless challenges in combat, it was the internal battle with trauma and addiction that became his most daunting mission. The aftermath led him into substance abuse, and despite multiple treatment attempts, true recovery remained elusive until a near-fatal overdose in 2021.
'I view this as God saying, 'Man, do something about this or this is all you're going to see for the rest of your life, as long or short as that may be,'' Morgan said.
Dr. Brian Wind, chief clinical officer for Regard Recovery, introduced Morgan, emphasizing the importance of trust and hope in the recovery process.
'As I shared with Kyle, just a sliver of hope on the horizon is all I needed,' Dr. Wind said. 'Just enough to push the door open and explore what a life in recovery might look like for me.'
Morgan, now more than three years sober, emphasized the importance of faith, accountability, and identity beyond one's profession in maintaining recovery.
'My identity was what I did, my profession. But I've learned that your profession cannot be your identity,' Morgan explained. 'I'm a grateful recovered alcoholic. I surrendered to Jesus Christ exactly a year after I got sober.'
Morgan and his wife, Erica, reside in Lillington, N.C., where they've been married for 20 years and are raising four children.
About Kyle Morgan & Blu Bearing Solutions
As a retired special operations forces veteran, Kyle Morgan leverages his extensive military background to empower law enforcement and private citizens through Blu Bearing Solutions. His training company focuses on building the 'protector' mindset and specializes in teaching active shooter and crisis response tactics, bringing battlefield strategies used by elite fighting forces to civilian preparedness.
Website: www.blubearing.com
About The Bluffs Addiction Campuses
The Bluffs Addiction Campuses in Sherrodsville, Ohio, is part of Regard Recovery's national footprint across the United States. The center provides evidence-based treatment programs including drug and alcohol detoxification, inpatient rehabilitation, and specialized tracks such as the Y6R program for veterans, law enforcement, and first responders. Located in the rolling hills of eastern Ohio, The Bluffs offers a tranquil setting for healing, growth, and self-reflection, supported by a comprehensive continuum of care.
About Your Six Recovery (Y6R)
Your Six Recovery (Y6R) is a specialized addiction treatment program created for law enforcement officers, veterans, and first responders. Built on the foundational principle of 'got your six'—a term meaning 'I've got your back'—the program offers a unique approach that honors the values of integrity and professionalism while providing critical support for individual healing.
The Bluffs Addiction Campuses in Sherrodsville, Ohio offers evidence-based addiction treatment, detox, inpatient rehab, and the specialized Y6R program for veterans and first responders.
Press inquiries
The Bluffs Addiction Campuses https://bluffsrehab.com/Jonathan Howard media@bluffsrehab.com (629) 246-29552650 Lodge Rd SW Sherrodsville, OH 44675
A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9de950b0-905a-4598-bfff-630f7c681891
Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1ea9b387-b4e9-41fc-a280-d96184c622e4
https://www.globenewswire.com/NewsRoom/AttachmentNg/2c8d6179-f3dc-488f-b0be-3bf1613577e4Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Medical Device Testing Market Size Attains USD 24.32 Bn by 2034
The global medical device testing market is valued at USD 10.77 billion in 2025 and is projected to grow to approximately USD 24.32 billion by 2034, expanding at a CAGR of 9.47% during the forecast period. Ottawa, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The global medical device testing market size was valued at USD 9.84 billion in 2024 and is projected to reach approximately USD 24.32 billion by 2034, expanding at a CAGR of 9.47% over the forecast period, according to a study published by Towards Healthcare, a sister firm of Precedence Research. A rise in the need for trustworthy and high-quality medical devices is propelling the expansion of the global market. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways Asia-Pacific led the global medical device testing market in 2024. North America is expected to witness rapid expansion during 2025-2034. By service, the biocompatibility tests segment was dominant in the market in 2024. By service, the chemistry tests segment is expected to register significant growth in the coming years. By phase, the clinical segment held the dominating share of the global medical device testing market in 2024. By phase, the preclinical segment is expected to grow at a notable CAGR during 2025-2034. Market Overview & Potential A process in which the evaluation of the safety, efficiency, and performance of medical devices is conducted, termed medical device testing. Across the globe, the global medical device testing market is experiencing growing regulatory strictness, technological breakthroughs, and a rising healthcare sector. In 2025, it comprises major developments in in-vitro diagnostics (IVD), and the execution of the EU's Medical Device Regulation (MDR) around the market. Usually, it encompasses the evaluation, functionality, durability, sterility, biocompatibility, electrical safety, and usability of the medical device. What are the Key Growth Drivers Involved in The Expansion of The Market? In 2025, several growth factors are impacting the overall development of the global medical device testing market. The growing geriatric population associated with chronic concerns is driving demand for diverse medical devices involved in diabetes management, mobility assistance, and remote patient monitoring. Along with this, an emerging strict regulatory landscape, such as the FDA and the EU's MDR, is offering strong testing guidelines for safety and efficacy. Majorly, different developing medical device producers, particularly startups, are highly outsourcing testing to specialized firms, resulting in market growth. Become a valued research partner with us - What are the Key Drifts Involved in the Market? In August 2025, BDC Laboratories, a leading player in cardiovascular device testing solutions, entered into a strategic partnership with the newly established Dilawri Cardiovascular Institute (DCI) to enhance focus on the development and clinical validation of cardiovascular medical devices. In October 2024, NAMSA, a leader in MedTech Contract Research Organization (CRO) offering end-to-end market access services, and TERUMO, a global player in medical technology, partnered to expand the regulatory approval and commercialization of Terumo's product portfolio. What is the Emerging Challenge in the Market? The need for significant investment in specialized equipment, skilled personnel, and ongoing compliance efforts is creating a major hindrance in the global medical device testing market. Alongside, the widespread requirement for specialized knowledge and skills in areas like biocompatibility, sterilization, and electrical safety is evolving into a barrier to the development of the market. Regional Analysis Why Did Asia Pacific Dominate the Market in 2024? Across the global medical device testing market, the Asia Pacific was dominant in 2024. China, India, and Japan are experiencing a vital expansion due to increasing economies and growing disposable incomes. This ultimately results in a rise in investment in the healthcare system and medical devices, propelling the adoption of various testing services. Additionally, faster advances in different technologies, such as miniaturization, digitalization, and the development of new materials, are enhancing the need for specialized testing March 2025, UL Solutions Inc., a major player in applied safety science, announced its expansion of Songshan Lake IoT Laboratory in Dongguan, China, to support manufacturers in navigating the complexities of connected product and wireless device testing and market access. What Made North America Significantly Grow in the Market in 2024? During 2025-2034, North America is predicted to expand at a rapid CAGR in the global medical device testing market. Merging high R&D investment by many medical device companies, like the adoption of technologies like AI and automation, in this region, is fueling overall market development. Also, North America is focusing on patient safety and regulatory compliance, especially in the US, which requires rigorous testing throughout the product January 2025, Argon Medical Devices enrolled the first patient in a US-based study exploring a newer catheter-based device for managing blood clots in the lungs. In June 2025, Ash, a leading at-home health testing platform, and Impilo, a leader in offering at-home healthcare, partnered to deliver feasible at-home health monitoring and testing nationwide. You can place an order or ask any questions, please feel free to contact us at sales@ Segmental Insights By service analysis Which Service Led the Medical Device Testing Market in 2024? The biocompatibility tests segment held the largest revenue share of the market in 2024. Around the globe, numerous medical device manufacturers are preferring biocompatibility testing to achieve market acceptance and develop a robust reputation for quality and safety. Along with this, these tests are important for reducing the risk of adverse reactions, infections, and other difficulties linked with medical devices. This leads to ensuring patient safety and improving device efficacy. Whereas the chemistry tests segment is predicted to grow rapidly during 2025-2034. Several advantages of this segment are the assessment of the possible toxicity of medical devices and confirming that they will not react negatively with the body. Additionally, the chemistry tests are widely employed in broader devices, from simple disposables to complex implants, to ensure their safety and regulatory compliance. Primarily, they comprise the identification of chemical compounds of a medical device and examination of probable risks linked with their presence, which further assist in biocompatibility assessment. By phase analysis How did the Clinical Segment Hold a Major Share of the Market in 2024? The clinical segment dominated the global medical device testing market in 2024. Usually, different phases of clinical trials offer significant real-world evidence that assists healthcare professionals in making informed decisions about device usage and expands the continuous optimization of medical devices. A surge in 3D printing and AI in medical device manufacturing is boosting the need for clinical trials to study the performance and safety of these new technologies. Also, the segment is driven by the accelerating need for advanced medical devices, a focus on patient safety and efficacy, and a rise in regulatory scrutiny. The preclinical segment is predicted to witness significant expansion in the studied years. Ongoing developments in biocompatibility testing, microbiology testing, and package validation are widely impacting the development of the preclinical phase of the market. Furthermore, various medical device industries, especially small-scale ones, have a shortage of resources or well-trained personnel to execute complete preclinical testing in-house. This further propels the demand for specialized preclinical testing service providers. Whereas, currently growing diverse chronic diseases are fueling demand for enhanced patient safety, which ultimately relies on the development of the preclinical phase. Get the latest insights on healthcare industry segmentation with our Annual Membership: Recent Developments In July 2025, Siemens Healthineers launched the CN-3000 and CN-6000 Hemostasis Systems for coagulation testing in Canada. In May 2025, Roche unveiled the Elecsys PRO-C3 test for the evaluation of the liver fibrosis severity in individuals with signs of metabolic dysfunction–associated steatotic liver disease (MASLD). In March 2025, Nelson Labs launched a groundbreaking rapid sterility testing to notably expedite product sterility results. In October 2024, UPM Biomedicals, the forerunner in producing high quality nanofibrillar cellulose for medical and life science applications, introduced FibGel, a natural injectable hydrogel for permanent implantable medical devices. Medical Device Testing Market Key Players SGS SA Laboratory Corporation of America Holdings Nelson Laboratories, LLC TÜV SÜD Charles River Laboratories Element Minnetonka North America Science Associates Inc. (NAMSA) Eurofins Scientific Pace Analytical Services LLC Intertek Group Plc WuXi AppTec Browse More Insights of Towards Healthcare: The global medical device contract manufacturing market is valued at USD 78.61 billion in 2024, expected to grow to USD 87.14 billion in 2025, and projected to reach approximately USD 220.57 billion by 2034, expanding at a CAGR of 10.86% between 2025 and 2034. The global medical device outsourcing market is estimated at USD 160.3 billion in 2024, rising to USD 180.59 billion in 2025, and forecasted to hit nearly USD 507.89 billion by 2034, advancing at a CAGR of 12.65% during 2025–2034. The global pain management devices market stands at USD 7.68 billion in 2024, increasing to USD 8.41 billion in 2025, and is anticipated to reach around USD 19.1 billion by 2034, growing at a CAGR of 9.54% over the forecast period. The global medical device CRO market is valued at USD 8.49 billion in 2024, set to rise to USD 9.25 billion in 2025, and projected to surpass USD 19.9 billion by 2034, at a CAGR of 8.98% between 2025 and 2034. The global wearable medical devices market is calculated at USD 42.78 billion in 2024, climbing to USD 53.68 billion in 2025, and expected to surge to nearly USD 408.61 billion by 2034, registering a strong CAGR of 25.57% from 2025 to 2034. The global implantable medical devices market is estimated at USD 97.17 billion in 2024, growing to USD 103.14 billion in 2025, and forecasted to reach around USD 176.33 billion by 2034, advancing at a CAGR of 6.14% during 2025–2034. The medical device gaskets & seals market was valued at USD 0.92 billion in 2023 and is projected to expand to USD 1.57 billion by 2034, progressing at a CAGR of 5% from 2024 to 2034. The 3D-printed medical devices market is expected to grow from USD 5.59 billion in 2025 to approximately USD 24.69 billion by 2034, witnessing a robust CAGR of 17.94% over the forecast period. The global endoscopy devices market size is valued at USD 61.1 billion in 2024, projected to increase to USD 63.44 billion in 2025, and estimated to reach USD 88.55 billion by 2034, registering a CAGR of 3.82% between 2025 and 2034. The global rehabilitation equipment market is valued at USD 17 billion in 2024, expected to rise to USD 18.42 billion in 2025, and projected to hit USD 37.34 billion by 2034, expanding at a CAGR of 8.34% from 2025 to 2034. Segments Covered in The Report By Service Biocompatibility Tests Cardiovascular Device's Biocompatibility Tests Orthopedic Device's Biocompatibility Tests Dental Implant Devices' Biocompatibility Tests Dermal Filler's Biocompatibility Tests General Surgery Implantation Devices Biocompatibility Tests Neurosurgical Implantation Devices Biocompatibility Tests Ophthalmic Implantation Device's Biocompatibility Tests Others Chemistry Test Chemical characterization (E&L) Analytical method development and validation Toxicological Risk Assessment and consulting Microbiology & Sterility Test Bioburden Determination Pyrogen & Endotoxin Testing Sterility Test & Validation Antimicrobial Testing Others Package Validation By Phase Preclinical Large animal research Biocompatibility Tests Chemistry Test Microbiology & Sterility Test Small animal research Biocompatibility Tests Chemistry Test Microbiology & Sterility Test Clinical By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: Immediate Delivery Available | Buy This Premium Research @ About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region: +44 778 256 0738 North America Region: +1 8044 4193 44 APAC Region: +91 9356 9282 04 Web: Our Trusted Data Partners Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | PinterestError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Larkspur Biosciences Announces Discovery of LRK-4189, a First-in-Class Degrader of the Lipid Kinase PIP4K2C, for the Treatment of Microsatellite Stable (MSS) Colorectal Cancer at the ACS Fall 2025 Meeting
First-in-human, Phase 1 Study of LRK-4189 to Begin in the Fourth Quarter CAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a company pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness, today announced the discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer (CRC) and other solid tumors. The announcement was made at a presentation Larkspur was invited to give at the prestigious MEDI First Time Disclosures: Breakthroughs on New Medicines session at ACS Fall 2025, a meeting of the American Chemical Society in Washington, DC. Cancer cells maintain their fitness by developing survival adaptations that foster escape from intrinsic and extrinsic mechanisms of cell death in conditions of stress. Phosphatidylinositol 5-phosphate 4-kinase, type II, gamma (PIP4K2C) is a lipid kinase associated with poor outcomes in a range of cancers including CRC and breast cancers. PIP4K2C is co-opted by cancer cells to increase their fitness by evading immune surveillance and adapting to stress. 'Genetic studies have long highlighted PIP4K2C as a key player in cancer stress adaptation, but its extremely low kinase activity made it resistant to conventional inhibition approaches,' said Catherine Sabatos-Peyton, PhD, CEO of Larkspur Biosciences. 'With our novel degrader, LRK-4189, we've finally unlocked this critical pathway. By reducing cancer cell fitness, triggering intrinsic apoptosis, and engaging the immune system to clear residual tumor cells, LRK-4189 has the potential to overcome the limitations of earlier therapies. We're excited to advance this promising therapy to the clinic later this year.' According to the American Cancer Society, in the United States, approximately 150,000 cases of CRC are diagnosed annually, with MSS CRC accounting for about 85% of all CRC cases. About LRK-4189 LRK-4189 is an orally bioavailable, selective degrader of PIP4K2C with subnanomolar potency in primary human cells. LRK-4189-mediated degradation of PIP4K2C leads to intrinsic cancer cell death and activates interferon signaling, triggering multiple killing mechanisms in difficult-to-treat MSS CRC cells. In vivo, LRK-4189 demonstrates dose dependent PKPD with single agent efficacy in multiple models of CRC and synergy with first-line standard of care chemotherapy. In primary human CRC patient-derived spheroids, 50% of patient samples respond to LRK-4189 with a preferential response in MSS CRC, which compares favorably to benchmark cetuximab in the same platform (35%). Cetuximab may be either a first- or second-line treatment in people with RAS wild type CRC. LRK-4189 has completed IND-enabling studies and expects to initiate a Phase 1 clinical trial in Q4 2025. About Larkspur Biosciences Larkspur Biosciences is pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness. Larkspur develops therapies that decrease cancer cell fitness and sensitizes the cells to intrinsic and immune-driven mechanisms of killing. The company is advancing first-in-class programs that target the adaptations cancer cells use to proliferate, invade tissue, and escape the immune system. LarkX, the company's proprietary bioinformatics platform, couples machine learning with tumor genetics to discover cancer cell fitness pathways that originate in the tumor and enrich clinical strategies for potential responders to its therapies across multiple types of cancer. Larkspur's founders include Lewis C. Cantley, PhD, professor of medicine at Dana-Farber Cancer Institute, professor of cell biology at Harvard Medical School; Vijay K. Kuchroo, DVM, PhD, professor of neurology at Harvard Medical School, senior scientist at Brigham and Women's Hospital; and Nathanael Gray, PhD, professor of chemical and systems biology at Stanford University. Visit us at and follow us on LinkedIn and X. Media Contact:Dan BoyleScientPRdan@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Dr. Ritesh Kalra Scholarship to Support Aspiring Medical Professionals
Dr. Ritesh Kalra Scholarship SECAUCUS, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- The Dr. Ritesh Kalra Scholarship for Medical Students is now accepting applications for its 2026 award cycle, offering a $1,000 prize to a deserving undergraduate student on the path to becoming a doctor. Established by acclaimed physician Dr. Ritesh Kalra, this initiative seeks to encourage academic excellence, foster a spirit of compassion in medicine, and provide financial assistance to future healthcare leaders. The scholarship will be awarded through an engaging essay contest, providing applicants with an opportunity to share their vision for the future of medicine. Students are invited to reflect on the balance between technological advancements in healthcare and the human connection that remains at the heart of patient care. The award is open to undergraduate students in accredited institutions who are committed to pursuing a medical career. 'This scholarship represents more than financial assistance—it's a way to inspire the next generation of physicians to uphold both innovation and empathy in their work,' said Dr. Kalra. 'Medicine is not only a science; it's a calling that requires skill, dedication, and a genuine desire to help others.' About Dr. Ritesh Kalra Dr. Ritesh Kalra is a highly respected internal medicine specialist with decades of service in both private practice and hospital settings. His career spans extensive clinical work, award-winning research, and mentorship of medical students. Trained across prestigious institutions in Poland, New York, and Georgia, Dr. Ritesh Kalra has earned repeated recognition as a Top Doctor in Internal Medicine from 2020 through 2025. Fluent in Hindi and Punjabi, he connects with a diverse patient population and has devoted his career to improving healthcare delivery and patient outcomes. His inspiration for creating the scholarship stems from his belief in the power of education and the critical role that young, motivated doctors will play in the future of global health. Application Details The Dr. Ritesh Kalra Scholarship for Medical Students is open to all undergraduate students enrolled in accredited U.S. institutions who are on an academic track toward becoming a physician. Applicants must submit a 750–1,000-word original essay responding to the following prompt: "In the rapidly evolving field of medicine, how can future doctors balance technological advancement with the human connection that lies at the heart of patient care? Share your thoughts, supported by personal experiences, observations, or aspirations." Submissions should demonstrate critical thinking, originality, and a strong personal commitment to the medical field. Important Dates Application Deadline: May 15, 2026 Winner Announcement: June 15, 2026 The winning essay will be selected by the scholarship review committee based on insight, clarity, creativity, and the ability to convey a compelling vision for the future of healthcare. The $1,000 award will be sent directly to the recipient to support their educational expenses. How to Apply Applicants should send their essay along with their full name, contact information, school name, and field of study to apply@ The subject line should read: Dr. Ritesh Kalra Scholarship Application. The scholarship reflects Dr. Ritesh Kalra's ongoing mission to support the academic journeys of aspiring doctors and to encourage them to integrate technological expertise with compassionate care. Through this program, he hopes to inspire students to pursue medicine not only as a career but as a lifelong service to humanity. Contact InformationSpokesperson: Dr. Ritesh KalraOrganization: Dr. Ritesh Kalra Scholarship for Medical StudentsWebsite: apply@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
